-

Prescription Antiparasitic Medication Information

This page provides information for Ivermectin tablets, 3 mg. This is a prescription medication approved for treating specific parasitic worm infections in humans. The information provided is for general knowledge only and does not replace professional medical advice.

Critical Safety & Usage Notice

This is a prescription medication. It is not available over-the-counter. Ivermectin is FDA-approved for specific parasitic conditions as determined by a healthcare provider. It is not approved for the prevention or treatment of COVID-19 or other viral illnesses. Using ivermectin incorrectly can cause serious harm.

Product & Approved Usage Details

• Active Ingredient: Ivermectin
• Dosage Strength: 3 mg per tablet
• Drug Class: Antiparasitic (avermectin)
• FDA-Approved Indications (Human Use):
  • Intestinal strongyloidiasis
  • Onchocerciasis (river blindness)
• Form: Oral Tablet

Essential Safety Information

• Not For COVID-19: The FDA has not authorized or approved ivermectin for use in preventing or treating COVID-19 in humans. Using it for this purpose can be dangerous.
• Different Formulations: Ivermectin formulations for animals (often in much higher doses) are very different from those for humans and are not safe for human consumption.
• Important Contraindication: Ivermectin is contraindicated in patients who are hypersensitive to any component of the product.
• Potential Side Effects: May include dizziness, nausea, diarrhea, skin rash, and fast heartbeat. In overdose situations or with inappropriate use, serious adverse effects such as hypotension, seizures, coma, and death have been reported.
• Drug Interactions: Can interact with other medications that increase its concentration in the blood, such as certain anti-seizure medicines, barbiturates, and benzodiazepines.
• Consult Your Doctor: Only a licensed healthcare provider can diagnose a parasitic infection and determine if this medication is appropriate. Always follow your doctors prescribed dosage exactly.